Patients who had a transient ischemic attack or stroke are at increased risk of experiencing recurrent cerebrovascular events. For this reason, secondary prevention of ischemic cerebrovascular disease is essential. Several modifiable, lifestyle-associated risk factors have been implicated, such as physical activity, smoking, and alcohol consumption. Established and emerging vascular risk factors are associated with an increased risk of stroke. Pharmacologic treatment, including the use of antiplatelet, antihypertensive, and lipid-lowering agents, has also been shown to reduce the risk of secondary cerebrovascular events. Surgical intervention, either open or endovascular, may be the preferred therapeutic option in well-defined subsets of patients. It is important to establish specific measures for the early detection and prevention of recurrent cerebrovascular disease. Therefore, further research and greater awareness in this field are needed.
Get full access to this article
View all access options for this article.
References
1.
Vickrey BG, Rector TS, Wickstrom SL, et al: Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke33:901-906, 2000.
2.
Burn J, Dennis M, Bamford J, et al: Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project. Stroke25:333-337, 1994.
3.
Lee IM, Hennekens CH, Berger K, et al: Exercise and risk of stroke in male physicians. Stroke30:1-6, 1999.
4.
Ellekjaer H, Holmen J, Ellekjaer E, et al: Physical activity and stroke mortality in women. Ten-year follow-up of the Nord-Trondelag Health Survey, 1984-1986. Stroke31:14-18, 2000.
5.
Leys D, Deplanque D, Mounier-Vehier C, et al: Stroke prevention: Management of modifiable vascular risk factors. J Neurol249:507-517, 2002.
6.
Berger K, Schulte H, Stogbauer F, et al: Incidence and risk factors for stroke in an occupational cohort: The PROCAM-Study. Prospective Cardiovascular Muenster Study. Stroke29:1562-1566, 1998.
7.
Robbins AS, Manson JE, Lee IM, et al: Cigarette smoking and stroke in a cohort of U.S. male physicians. Ann Intern Med120:458-462, 1994.
8.
Shinton R, Beevers G: Meta-analysis of relation between cigarette smoking and stroke. BMJ298:789-794, 1989.
9.
Wolf PA, D’Agostino RB, Kannel WB, et al: Cigarette smoking as a risk factor for stroke: The Framingham Study. JAMA259:1025-1029, 1988.
10.
Kawachi I, Colditz GA, Stampfer MJ, et al: Smoking cessation and decreased risk of stroke in women. JAMA269:232-236, 1993.
11.
Hankey GJ, Jamrozik K, Broadhurst RJ, et al: Long-term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke29:2491-2500, 1998.
12.
Tsiara S, Elisaf M, Mikhailidis DP: Influence of smoking on predictors of vascular disease. Angiology54:507-530, 2003.
13.
Camargo CA Jr: Moderate alcohol consumption and stroke. The epidemiologic evidence. Stroke20:1611-1626, 1989.
14.
Stampfer MJ, Colditz GA, Willett WC, et al: A prospective study of moderate alcohol consumption and the risk of coronary disease and stroke in women. N Engl J Med319:267-273, 1988.
15.
Berger K, Ajani UA, Kase CS, et al: Light-to-moderate alcohol consumption and risk of stroke among U.S. male physicians. N Engl J Med341:1557-1564, 1999.
16.
Truelsen T, Gronbaek M, Schnohr P, et al: Intake of beer, wine, and spirits and risk of stroke: The Copenhagen City Heart Study. Stroke29:2467-2472, 1998.
17.
Juvela S, Hillbom M, Numminen H, et al: Cigarette smoking and alcohol consumption as risk factors for aneurysmal subarachnoid hemorrhage. Stroke24:639-646, 1993.
18.
Juvela S, Hillbom M, Palomaki H: Risk factors for spontaneous intracerebral hemorrhage. Stroke26:1558-1564, 1995.
19.
Sacco RL, Shi T, Zamanillo MC, et al: Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: The Northern Manhattan Stroke Study. Neurology44:626-634, 1994.
20.
Iso H, Jacobs DR Jr, Wentworth D, et al: Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med320:904-910, 1989.
21.
Neaton JD, Blackburn H, Jacobs D, et al: Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med152:1490-1500, 1992.
22.
Neaton JD, Wentworth DN, Cutler J, et al: Risk factors for death from different types of stroke. Ann Epidemiol3:493-499, 1993.
23.
Joensuu T, Salonen R, Windblad I, et al: Determinants of femoral and carotid artery atherosclerosis. J Intern Med236:79-84, 1994.
24.
Gariepy J, Simon A, Massonneau M, et al: Wall thickening of carotid and femoral arteries in male subjects with isolated hypercholesterolemia. PCVMETRA Group. Prevention Cardio-Vasculaire en Medecine du Travail. Atherosclerosis113:141-151, 1995.
25.
Wittekoek ME, de Groot E, Prins MH, et al: Differences in intima-media thickness in the carotid and femoral arteries in familial hypercholesterolemic heterozygotes with and without clinical manifestation of cardiovascular disease. Atherosclerosis146:271-279, 1999.
26.
Cheng KS, Mikhailidis DP, Hamilton G, et al: A review of the carotid and femoral intima-media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors. Cardiovasc Res54:528-538, 2002.
27.
Aminbakhsh A, Mancini GB: Carotid intima-media thickness measurement: What defines an abnormality? A systematic review. Clin Invest Med22:149-157, 1999.
28.
Lindenstrom E, Boysen G, Nyboe J: Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: The Copenhagen City Heart Study. BMJ309:11-15, 1994.
29.
Cholesterol, diastolic blood pressure and stroke. 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective Studies Collaboration. Lancet346:1647-1653, 1995.
30.
Amarenco P, Labreuche J, Lavallee P, et al: Statins in stroke prevention and carotid atherosclerosis. Systematic review and up-to-date meta-analysis. Stroke2004 Oct 28 [Epub ahead of print].
31.
Bloomfield RH, Davenport J, Babikian V, et al, VA-HIT Study Group: Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation103:2828-2833, 2001.
32.
Law MR, Wald NJ, Rudnicka AR: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysisBMJ326:1423-1430, 2003.
33.
Rizos E, Mikhailidis DP: Are high-density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention? Cardiovasc Res52:199-207, 2001.
34.
Di Napoli M: Benefits of statin in cerebrovascular disease. Curr Opin Invest Drugs5:295-305, 2004.
35.
Gresser U, Gathof BS: Atorvastatin: Gold standard for prophylaxis of myocardial ischemia and stroke—comparison of the clinical benefits of statins on the basis of randomized controlled endpoint studies. Eur J Med Res9:1-17, 2004.
36.
Collins R, Armitage J, Parish S, et al, Heart Protection Study Collaborative Group: Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet363:757-767, 2004.
37.
Jurgens G, Koltringer P: Lipoprotein (a) in ischemic cerebrovascular disease: A new approach to the assessment of risk for stroke. Neurology37:513-515, 1987.
38.
Lindgren A, Nilsson-Ehle P, Norrving B, et al: Plasma lipids and lipoproteins in subtypes of stroke. Acta Neurol Scand86:572-578, 1992
39.
Vavernova H, Novotny D, Ficker L, et al: Lipoprotein (a): A genetic risk factor for early ischemic cerebrovascular stroke. Vnitr Lek39:979-987, 1993.
40.
Milionis HJ, Winder AF, Mikhailidis DP: Lipoprotein (a) and stroke. J Clin Pathol53:487-496, 2000.
41.
Major ongoing stroke trials. Stroke34:1-28, 2003.
42.
Boysen G, Brander T, Christensen H, et al: Homocysteine and risk of recurrent stroke. Stroke34:1258-1261, 2003.
43.
Li Z, Sun L, Zhang H, et al: Elevated plasma homocysteine was associated with hemorrhagic and ischemic stroke, but methylenetetrahydrofolate reductase gene C677T polymorphism was a risk factor for thrombotic stroke: A Multicenter Case-Control Study in China. Stroke34:2085-2090, 2003.
44.
Fernandez-Miranda C, Paz M, Aranda JL, et al: Homocysteine and progression of carotid atherosclerosis in patients with coronary disease. Med Clin (Barc)121:561-564, 2003.
45.
Wald DS, Law M, Morris JK: Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ325:1202-1210, 2002.
46.
Wald NJ, Law MR: A strategy to reduce cardiovascular disease by more than 80%. BMJ326:1419-1424, 2003.
47.
Hodis HN, Mack WJ, Lobo R, et al: Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med135:939-953, 2001.
48.
Viscoli CM, Brass LM, Kernan WN, et al: A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med345:1243-1249, 2001.
49.
Writing Group for the Women’s Health Initiative Investigators: Risk and benefits of estrogens plus progestin in healthy postmenopausal women. JAMA288:321-333, 2002.
50.
Ylikorkala O: HRT as secondary prevention of cardiovascular disease. Maturitas47:315-318, 2004.
51.
La Vecchia C: Oral contraceptives, menopause hormone replacement therapy, and risk of stroke. Maturitas47:265-268, 2004.
52.
Rantanen K, Tatlisumak T: Secondary prevention of ischemic stroke. Curr Drug Targets5:457-472, 2004.
53.
Hier DB, Foulkes MA, Swiontoniowski M, et al: Stroke recurrence within 2 years after ischemic infarction. Stroke22:155-161, 1991.
54.
Hillen T, Coshall C, Tilling K, et al: Cause of stroke recurrence is multifactorial: Patterns, risk factors, and outcomes of stroke recurrence in the South London Stroke Register. Stroke34:1457-1463, 2003.
55.
Daskalopoulou SS, Mikhailidis DP, Elisaf M: Prevention and treatment of the metabolic syndrome. Angiology2005, in press.
56.
Elisaf M, Mikhailidis DP: Statins and renal function. Angiology53:493-502, 2002.
57.
Rahman M, Brown CD, Coresh J, et al, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group: The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Arch Intern Med164:969-976, 2004.
58.
Daskalopoulou SS, Athyros VG, Elisaf M, et al: Uric acid levels and vascular disease. Curr Med Res Opin20:951-954, 2004.
59.
Daskalopoulou SS, Mikhailidis DP: Biochemical and clinical relevance of hyperuricaemia. Curr Pharm Dis2005, in press.
60.
Athyros VG, Mikhailidis DP, Papageorgiou AA, et al: The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the GReek Atorvastatin and Coronary heart disease Evaluation (GREACE) study. J Clin Pathol57:728-734, 2004.
61.
Athyros VG, Elisaf M, Papageorgiou AA, et al, GREACE Study Collaborative Group: Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) study. Am J Kidney Dis43:589-599, 2004.
62.
Weir CJ, Muir SW, Walters MR, et al: Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke34:1951-1956, 2003.
63.
The Dutch TIA Trial Study Group: Predictors of major vascular events in patients with transient ischemic attack or nondisabling stroke. Stroke24:527-531, 1993.
64.
Clark TG, Murphy MF, Rothwell PM: Long-term risks of stroke, myocardial infarction and vascular death in patients with a non-recent transient ischaemic attack. J Neurol Neurosurg Psychiatry74:577-580, 2003.
65.
UK-TIA Study Group: The United Kingdom Transient Ischemic Attack (UK-TIA) Aspirin Trial: Final results. J Neurol Neurosurg Psychiatry54:1044-1054, 1991.
66.
Rothwell PM, Howard SC, Power DA, et al, for the Cerebrovascular Cohort Studies Collaboration: Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5,113 patients with transient ischemic attack and minor ischemic stroke. Stroke35:2300-2305, 2004.
67.
Maresca G, Di Blasio A, Marchioli R, et al: Measuring plasma fibrinogen to predict stroke and myocardial infarction. Arterioscler Thromb Vasc Biol19:1368-1377, 1999.
68.
Tanne D, Benderly M, Goldbourt U, et al, Bezafibrate Infarction Prevention Study Group: A prospective study of plasma fibrinogen levels and the risk of stroke among participants in the Bezafibrate Infarction Prevention Study. Am J Med111:457-463, 2001.
69.
Mohr JP, Thompson JL, Lazar RM, et al and the Warfarin-Aspirin Recurrent Stroke Study Group: A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med345:1444-1451, 2001.
70.
Petty GW, Brown RD Jr, Whisnant JP, et al: Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention. A population-based study. Ann Intern Med130:14-22, 1999.
71.
European Atrial Fibrillation Trial Study Group: Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) study group. Lancet342:1255-1262, 1993.
72.
CAPRIE Steering Committee: A randomized, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE). Lancet348:1329-1339, 1996.
73.
Hass WK, Easton JD, Adams HP Jr, et al: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients: Ticlopidine Aspirin Stroke Study Group. N Engl J Med321:501-507, 1989.
74.
Harbison JW: Ticlopidine versus aspirin for the prevention of recurrent stroke. Analysis of patients with minor stroke from the Ticlopidine Aspirin Stroke Study. Stroke23:1723-1727, 1992.
75.
Diener HC, Cunha L, Forbes C, et al: European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci143:1-13, 1996.
76.
DeSchryver EL: Design of ESPRIT: an international randomized trial for secondary prevention after nondisabling cerebral ischemia of arterial origin. European/Australian Stroke Prevention in Reversible Ischemia Trial (ESPRIT) Group. Cerebrovasc Dis10:147-150, 2000.
77.
Hankey GJ, Sudlow CL, Dunbabin DW: Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials. Stroke31:1779-1784, 2000.
78.
Hankey GJ, Warlow CP: Treatment and secondary prevention of stroke: Evidence, costs, and effects on individuals and populations. Lancet354:1457-1363, 1999.
79.
Albers GW, Amarenco P: Combination therapy with clopidogrel and aspirin. Can the CURE results be extrapolated to cerebrovascular patients? Stroke32:2948-2949, 2001.
80.
Diener HC, Bogousslavsky J, Brass ML, et al, on behalf of the MATCH investigators: Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): Randomized, double-blind, placebo-controlled trial. Lancet364:331-337, 2004.
81.
Robless P, Mikhailidis DP, Stansby G: Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg88:787-800, 2001.
Post-Stroke antihypertensive treatment study: A preliminary result. PATS collaborating group. Chin Med J (Engl)108:710-717, 1995.
84.
Rodgers A, MacMahon S, Gamble G, et al: Blood pressure and risk of stroke in patients with cerebrovascular disease. The United Kingdom Transient Ischemic Attack Collaborative Group. BMJ313:147, 1996.
85.
Irie K, Yamaguchi T, Minematsu K, et al: The J-curve phenomenon in stroke recurrence. Stroke24:1844-1849, 1993.
86.
Yusuf S, Sleight P, Pogue J, et al: Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcome Prevention Evaluation Study Investigators. N Engl J Med342:145-153, 2000.
87.
Dahlof B, Devereux RB, Kjeldsen SE, et al, and the LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet359:995-1003, 2002.
88.
PROGRESS Management Committee: Blood pressure lowering for the secondary prevention of stroke: Rationale and design for PROGRESS. Perindopril Protection Against Recurrent Stroke Study. J Hypertens14(suppl):S41-S45, 1996.
89.
PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack. Lancet358:1033-1041, 2001.
90.
Rashid P, Leonardi-Bee J, Bath P: Blood pressure reduction and secondary prevention of stroke and other vascular events: A systematic review. Stroke34:2741-2748, 2003.
91.
Rothwell PM, Gibson R, Warlow CP: Interrelation between plaque surface morphology and degree of stenosis on carotid angiograms and the risk of ischemic stroke in patients with symptomatic carotid stenosis. On behalf of the European Carotid Surgery Trialists’ Collaborative Group. Stroke31:615-621, 2000.
92.
North American Symptomatic Carotid Endarterectomy Trial Collaborators: Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med325:445-453, 1991.
93.
Droste DW, Dittrich R, Kemeny V, et al: Prevalence and frequency of microembolic signals in 105 patients with extracranial carotid artery occlusive disease. J Neurol Neurosurg Psychiatry67:525-528, 1999.
94.
Molloy J, Markus H: Asymptomatic embolization predicts stroke and TIA risk in patients with carotid artery stenosis. Stroke30:1440-1443, 1999.
95.
Siebler M, Kleinschmidt A, Sitzer M: Cerebral microembolism in symptomatic and asymptomatic high-grade internal carotid artery stenosis. Neurology44:615-618, 1994.
96.
Ringelstein EB, Droste DW, Babikian VL, et al: Consensus on microembolus detection by TCD. International consensus group on microembolus detection. Stroke29:725-729, 1998.
97.
Daskalopoulou SS, Daskalopoulos ME, Theocharis S, et al: Identifying the high-risk carotid atherosclerotic plaque. Presented at the Society of Vascular Surgery annual meetingJune 3-6, 2004, Anaheim, CA, USA. Scientific program, p 142.
98.
Biasi GM, Froio A, Diethrich EB, et al: Carotid plaque echolucency increases the risk of stroke in carotid stenting. The Imaging in Carotid Angioplasty and Risk of Stroke (ICAROS) Study. Circulation110:756-762, 2004.
99.
Bettmann MA, Katzen BT, Whisnant J, et al: Carotid stenting and angioplasty: A statement for Health-care Professionals from the Councils on Cardiovascular Radiology, Stroke, Cardio-Thoracic and Vascular Surgery, Epidemiology, and Prevention, and Clinical Cardiology, American Heart Association. Circulation97:121-123, 1998.
100.
Kim JK, Ahn JY, Lee BH, et al: Elective stenting for symptomatic middle cerebral artery stenosis presenting as transient ischaemic deficits or stroke attacks: Short term arteriographical and clinical outcome. J Neurol Neurosurg Psychiatry75:847-851, 2004
101.
Qureshi AI, Knape C, Maroney J, et al: Multicenter clinical trial of the NexStent coiled sheet stent in the treatment of extracranial carotid artery stenosis: Immediate results and late clinical outcomes. J Neurosurg99:264-270, 2003.
102.
Chio FL Jr, Liu MW, Khan MA, et al: Effectiveness of elective stenting of common carotid artery lesions in preventing stroke. Am J Cardiol92:1135-1137, 2003.
103.
CAVATAS Investigators: Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): A randomised trial. Lancet357:1729-1737, 2001.
104.
Dietz A, Berkefeld J, Theron JG, et al: Endovascular treatment of symptomatic carotid stenosis using stent placement. Long-term follow-up of patients with a balanced surgical risk/benefit ratio. Stroke32:1855-1859, 2001.
105.
Ohki T, Veith FJ, Grenell S, et al: Initial experience with cerebral protection devices to prevent embolization during carotid artery stenting. J Vasc Surg36:1175-1185, 2002.
106.
Mozes G, Sullivan TM, Torres-Russotto DR, et al: Carotid endarterectomy in the SAPHIRE-eligible high-risk patients: Implications for selecting patients for carotid angioplasty and stenting. J Vasc Surg39:958-966, 2004.
107.
Andaluz N, Zuccarello M: Evidence-based surgical treatment of carotid stenosis. Literature review. J Neurosurg Sci48:1-9, 2004.
108.
Roubin GS, New G, Iyer SS, et al: Immediate and late clinical outcomes of carotid artery stenting in patients with symptomatic and asymptomatic carotid artery stenosis: A 5-year prospective analysis. Circulation103:532-537, 2001.
109.
Cremonesi A, Castriota F, Manetti R, et al: Endovascular treatment of carotid atherosclerotic disease: Early and late outcome in a nonselected population. Ital Heart J1:801-809, 2000.
110.
Topol EJ, Yadav JS: Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation101:570-580, 2000.
111.
Mathur A, Roubin GS, Iyer SS, et al: Predictors of stroke complicating carotid artery stenting. Circulation97:1239-1245, 1998.
112.
Ackerstaff RG, Moons KG, van de Vlasakker CJ, et al: Association of intraoperative transcranial Doppler monitoring variables with stroke from carotid endarterectomy. Stroke31:1817-1823, 2000.
113.
Jaeger HJ, Mathias KD, Hauth E, et al: Cerebral ischemia detected with diffusion-weighted MR imaging after stent implantation in the carotid artery. Am J Neuroradiol23:200-207, 2002.
114.
Jordan WD Jr, Voellinger DC, Doblar DD, et al: Microemboli detected by transcranial Doppler monitoring in patients during carotid angioplasty versus carotid endarterectomy. Cardiovasc Surg7:33-38, 1999.
115.
Cremonesi A, Manetti R, Setacci F, et al: Protected carotid stenting. Clinical advantages and complications of embolic protection devices in 442 consecutive patients. Stroke34:1936-1941, 2003.
116.
Reimers B, Corvaja N, Moshiri S, et al: Cerebral protection with filter devices during carotid artery stenting. Circulation104:12-15, 2001.
117.
Whitlow PL, Lylyk P, Londero H, et al: Carotid artery stenting protected with an emboli containment system. Stroke33:1308-1314, 2002.
118.
Mas JL, Chatellier G, Beyssen B; EVA-3S Investigators: Carotid angioplasty and stenting with and without cerebral protection: Clinical alert from the Endarterectomy Versus Angioplasty in Patients With Symptomatic Severe Carotid Stenosis (EVA-3S) trial. Stroke35:e18-e20, 2004.
119.
Kastrup A, Groschen K, Krampf H, et al: Early outcome of carotid angioplasty and stinting with and without cerebral protection devices: A systematic review of the literature. Stroke34:813-819, 2003.
120.
Cernetti C, Reimers P, Picciolo A, et al: Carotid artery stenting with cerebral protection in 100 consecutive patients: Immediate and two-year follow-up results. Ital Heart J4:695-700, 2003.
121.
Reimers B, Schluter M, Castriota F, et al: Routine use of cerebral protection during carotid artery stenting: Results of a multicenter registry of 753 patients. Am J Med116:217-222, 2004.
122.
Rath PC, Lakshmi G, Agarwala M, et al: Carotid artery stenting with filter protection. Indian Heart J55:241-244, 2003.
123.
Henry M, Polydorou A, Henry I, et al: Carotid angioplasty under cerebral protection with the Percu-Surge GuardWire System. Cathet Cardiovasc Interv61:293-305, 2004.
124.
Bosiers M, Peeters P, Verbist J, et al: Belgian experience with FilterWire EX in the prevention of embolic events during carotid stenting. J Endovasc Ther10:695-701, 2003.
125.
Adami CA, Scuro A, Spinamano L, et al: Use of the Parody anti-embolism system in carotid stenting: Italian trial results. J Endovasc Ther9:147-154, 2002.
126.
Al-Mubarak N, Colombo A, Gaines PA, et al: Multicenter evaluation of carotid artery stenting with a filter protection system. J Am Coll Cardiol39:841-846, 2002.
127.
Guimaraens L, Sola MT, Matali A, et al: Carotid angioplasty with cerebral protection and stenting: Report of 164 patients (194 carotid percutaneous transluminal angioplasties). Cerebrovasc Dis13:114-119, 2002.
128.
Jaeger H, Mathias K, Drescher R, et al: Clinical results of cerebral protection with a filter device during stent implantation of the carotid artery. Cardiovasc Intervent Radiol24:249-256, 2001.
129.
Parodi JC, La Mura R, Ferreira LM, et al: Initial evaluation of carotid angioplasty and stenting with three different cerebral protection devices. J Vasc Surg32:1127-1136, 2000.
130.
Higashida RT, Meyers PM, Phatouros CC, et al, Technology Assessment Committees of the American Society of Interventional; Therapeutic Neuroradiology and the Society of Interventional Radiology: Reporting standards for carotid artery angioplasty and stent placement. Stroke35:e112-e134, 2004.
131.
Athyros VG, Mikhailidis DP, Papageorgiou AA, et al, for the GREACE Study Collaborative Group: Effect of Statins and Aspirin Alone and in Combination on Clinical Outcome in Dyslipidaemic Patients with Coronary Heart Disease. A subgroup analysis of the GREACE Study. Platelets2005, in press.
132.
Hennekens CH, Sacks FM, Tonkin A, et al: Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: Randomized and observational comparisons of secondary prevention trials and their meta-analyses. Arch Intern Med164:40-44, 2004.
133.
Athyros VG, Mikhailidis DP, Papageorgiou AA, et al: Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens18:781-788, 2004.
134.
Sever PS, Dahlof B, Poulter NR, et al, for ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOTLLA): A multicentre randomised controlled trial. Lancet361:1149-1158, 2003.
135.
Wierzbicki AS, Mikhailidis DP, Wray R, et al: Statinfibrate combination: Therapy for hyperlipidemia: A review. Curr Med Res Opin19:155-168, 2003.
136.
Tegos TJ, Kalodiki E, Daskalopoulou SS, et al: Stroke: Epidemiology, clinical picture, and risk factors—Part I of III. Angiology51:793-808, 2000.
137.
Rudd AG, Lowe D, Hoffman A, et al: Secondary prevention for stroke in the United Kingdom: Results from the National Sentinel Audit of Stroke. Age Ageing33:280-286, 2004.
